RBC reiterates Gilead at outperform

Gilead Sciences Inc. was reiterated by RBC Capital Markets analyst Jason Kantor at outperform, average risk. The company's reported second-quarter results exceeded the analyst's expectations, in particular in Truvada sales and earnings per share. Total revenue was $685 million, compared with RBC's estimate of $677 million. GAAP earnings per share of $0.56 beat the analyst's forecast by 2 cents. RBC increased its forecast to $1.97 billion from $1.94 billion. Shares of the Foster City, Calif.-based biopharmaceutical company were up 36 cents, or 0.61%, at $59.71 on volume of 6,774,323 shares versus the three-month running average of 5,774,323 shares. (Nasdaq: GILD)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.